# Evaluating the Safety and Immunogenicity of PENNVAX®-GP DNA Vaccine and IL-12 Plasmid, Delivered Via Intradermal or Intramuscular Electroporation in Healthy, HIV-Uninfected Adults

> **NCT02431767** · PHASE1 · COMPLETED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 94 (actual)

## Conditions studied

- HIV Infections

## Interventions

- **BIOLOGICAL:** PENNVAX®-GP HIV-1 DNA vaccine
- **BIOLOGICAL:** Interleukin-12 (IL-12) DNA adjuvant
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT02431767
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-08
- **Primary completion:** 2017-06-08
- **Final completion:** 2017-12-20
- **Target enrollment:** 94 (ACTUAL)
- **Last updated:** 2021-10-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02431767

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02431767, "Evaluating the Safety and Immunogenicity of PENNVAX®-GP DNA Vaccine and IL-12 Plasmid, Delivered Via Intradermal or Intramuscular Electroporation in Healthy, HIV-Uninfected Adults". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02431767. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*